Investment
Features
FeesSafety
Academy
More
Pluang+

XRP Ledger proposes new single-asset vaults and fixed-term lending, pending validator approval.

Protocol Fundamentals
23 Sep 2026
Tokenpost
View Source
Neutral
XRP Ledger proposes new single-asset vaults and fixed-term lending, pending validator approval.

The XRP Ledger is considering protocol updates to introduce single-asset vaults and fixed-term, uncollateralized lending. These changes would allow multiple depositors to pool one asset into vaults and issue shares, while loans could be funded without on-ledger collateral. The lending protocol would manage loans, but risk assessment remains with external lenders. The proposal is currently open for validator voting, requiring over 80% support for activation, but no activation date is set yet.

The XRP Ledger lending protocol update is under validator voting. For readers following cryptocurrency markets, here is Pluang's snapshot as of Sep 23, 2026 21:02 WIB: 27 of 50 major cryptocurrencies rose while 22 fell. Notable moves include ONE down 17.42% at Rp56, GRT up 12.89% at Rp484, and BAL up 11.14% at Rp16.297.

More News

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...

Analyst Insights
Bullish
1 hour ago
BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...

Analyst Insights
Bearish
1 hour ago
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...

Analyst Insights
Bullish
2 hours ago
Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...

Analyst Insights
Bullish
2 hours ago
Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App